组蛋白去乙酰化酶抑制剂在肿瘤治疗中的作用机制研究进展  

Progress on the mechanism of Histone deacetylase inhibitors in tumor therapy

作　　者：姜吉铠 李勐[1] 孙大康[1] 刘冉 JIANG Jikai;LI Meng;SUN Dakang;LIU Ran(Affiliated Hospital of Binzhou Medical College,Binzhou,Shandong 256603,China)

机构地区：[1]滨州医学院附属医院,山东滨州256603

出　　处：《医药前沿》2021年第27期30-31,共2页Journal of Frontiers of Medicine

摘　　要：近年来伴随着人们居住环境与生活习惯的改变,肿瘤发生率不断升高,威胁广大群众生命安全。细胞分化、异常增殖、浸润性、生长失控、转移性等是肿瘤的典型特征,很多肿瘤在早期缺乏典型症状,以至于很多患者在确诊时已经属于中晚期,错过了最佳的手术治疗时机。伴随着医疗技术的不断发展与进步,关于肿瘤的发病机制以及进展过程得到了更多的研究,其中发现组蛋白去乙酰化酶(HDACs)在肿瘤的发生与发展过程中扮演着重要的角色,相反组蛋白去乙酰化酶抑制剂(HDACi)在则调控关键的抑制肿瘤蛋白与原癌基因中发挥重要作用,被当作极具潜力的一类抗肿瘤药物。本文通过查阅相关文献,就HDACi在肿瘤中的应用进行综述。In recent years,with the changes in people’s living environment and living habits,the incidence of tumors has continued to increase,threatening the lives of the general public.Cell differentiation,abnormal proliferation,invasiveness,uncontrolled growth,metastasis,etc.are typical characteristics of tumors.Many tumors lack typical symptoms in the early stage,so that many patients are already in the middle and advanced stages at the time of diagnosis and miss the best opportunity for surgical treatment.With the continuous development and advancement of medical technology,more studies have been conducted on the pathogenesis and progression of tumors.Among them,it has been found that Histone Deacetylase(HDACs)plays an important role in the occurrence and development of tumors.On the contrary,Histone Deacetylase Inhibitors(HDACi)play an important role in regulating key tumor proteins and proto-oncogenes,and are regarded as a class of anti-tumor drugs with great potential.This article briefly reviewed the application of HDACi in tumors by consulting related literature,and the details are shown below.

关 键 词：组蛋白去乙酰化酶抑制剂 肿瘤 表观遗传 

分 类 号：R730[医药卫生—肿瘤]